{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:18:26Z","timestamp":1787879906793,"version":"build-2784847793"},"reference-count":17,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The evaluation of pharmacokinetic interactions is based on the knowledge of\n                        enzymatic metabolization by cytochrome 450 enzymes or cellular transport\n                        processes. Research on the metabolism of pipamperone, an antipsychotic of\n                        the butyrophenone family, has not yet yielded conclusive results. In the\n                        present in vitro study, human cytochrome enzymes were investigated for their\n                        possible involvement in the metabolism of pipamperone.<\/jats:p>\n                  <jats:p>The recombinant human cytochrome enzymes tested, i.e. CYP1A2, CYP2B6, CYP2C9,\n                        CYP2C19, CYP2D6, and CYP3A4, were commercially available. The U.S. Food and\n                        Drug Administration-recommended clinical index substrates were used to\n                        establish appropriate incubation conditions for each enzyme. All substrates\n                        and their metabolites were analyzed by gas chromatography\u2013mass spectrometry.\n                        After incubation, the amount of metabolites formed and the concentration of\n                        remaining pipamperone were measured. In addition, the metabolites from these\n                        in vitro experiments were compared with the metabolites found in the urine\n                        of pipamperone-treated patients and with those produced in a cell culture\n                        experiment.<\/jats:p>\n                  <jats:p>Overall, various cytochrome enzymes showed a low turnover of pipamperone.\n                        Only CYP2D6 and CYP3A4 caused statistically significant changes in both a\n                        decrease in pipamperone concentrations and an increase in metabolites.\n                        CYP3A4 proved to be the isoform that metabolized pipamperone most strongly,\n                        producing the same metabolite as all other CYP isoenzymes. It is noteworthy\n                        that this and other metabolites were also detected in the patients'\n                        urine samples.<\/jats:p>\n                  <jats:p>Our results suggest that, alongside the tested cytochrome enzymes, other\n                        phase I metabolizing systems likely play a role in pipamperone\n                        metabolism.<\/jats:p>","DOI":"10.1055\/a-2894-5577","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:09:31Z","timestamp":1787180971000},"source":"Crossref","is-referenced-by-count":0,"title":["Pipamperone metabolism by various recombinant cytochrome\n                    preparations"],"prefix":"10.1055","author":[{"given":"Tamara","family":"Pfaff","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology and Toxicology, Rostock\n                    University Medical Center, Germany","place":["Rostock"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Hinz","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology and Toxicology, Rostock\n                    University Medical Center, Germany","place":["Rostock"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo I.","family":"Walther","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology and Toxicology, Rostock\n                    University Medical Center, Germany","place":["Rostock"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40262-020-00894-y","article-title":"Pipamperone population pharmacokinetics related to effectiveness and side\n                    effects in children and adolescents","volume":"59","author":"S M Kloosterboer","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3238\/arztebl.2011.0687","article-title":"QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes","volume":"108","author":"K Wenzel-Seifert","year":"2011","journal-title":"Dtsch Arztebl Int"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/dta.2574","article-title":"Postmortem findings of pipamperone after fatal intoxications and its\n                    distribution in body fluids and tissues","volume":"11","author":"K Henning","year":"2019","journal-title":"Drug Test Anal"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology:\n                    Update 2017","volume":"51","author":"C Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"ref5","first-page":"430","article-title":"Pharmacokinetics of pipamperone from three different tablet formulations","volume":"52","author":"G E Potgieter","year":"2002","journal-title":"Arzneim Forsch Drug Res"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0378-4347(00)82862-5","article-title":"Mass spectral characterization of urinary pipamperone metabolites and\n                    high-performance liquid chromatography assay for pipamperone plasma levels","volume":"491","author":"C K\u00f6ppel","year":"1989","journal-title":"J Chromatogr"},{"key":"ref7","first-page":"263","article-title":"Basic review of the cytochrome P450 system","volume":"4","author":"A M McDonnell","year":"2013","journal-title":"J Adv Pract Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00008571-199204000-00004","article-title":"Biotransformation of caffeine, paraxanthine, theobromine and theophylline by\n                    cDNA-expressed human CYP1A2 and CYP2E1","volume":"2","author":"L Gu","year":"1992","journal-title":"Pharmacogenet"},{"key":"ref9","volume-title":"Mass spectral and GC data of drugs, poisons, pesticides, pollutants and their\n                    metabolites","author":"H H Maurer","year":"2011"},{"key":"ref10","volume-title":"Rapid identification and production of metabolites using CypExpress\u2122 2D6, 3A4\n                    and 2C9","author":"M Subramanian","year":"2014"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1006\/abbi.2001.2499","article-title":"Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme\n                    activity","volume":"393","author":"C Rodr\u00edguez-Antona","year":"2001","journal-title":"Arch Biochem Biophys"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1021\/tx0600090","article-title":"Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to\n                    pyridinium metabolites","volume":"19","author":"K M Avent","year":"2006","journal-title":"Chem Res Toxicol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1026317929335","article-title":"Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol","volume":"17","author":"J Fang","year":"1997","journal-title":"Cell Mol Neurobiol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/sj.npp.1300213","article-title":"Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese\n                    psychiatric population","volume":"28","author":"T Someya","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acschemneuro.7b00018","article-title":"Classics in chemical neuroscience: Haloperidol","volume":"8","author":"M W Tyler","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00003088-199937060-00001","article-title":"Pharmacokinetics of haloperidol. An update","volume":"37","author":"S Kudo","year":"1999","journal-title":"Clin Pharmacokin"},{"key":"ref17","first-page":"237","volume-title":"Evaluation of the clearance mechanism of non-CYP-mediated drug metabolism and\n                    DDI as a victim drug","author":"A Ghosal","year":"2020"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2894-5577.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:51:49Z","timestamp":1787878309000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2894-5577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":17,"URL":"https:\/\/doi.org\/10.1055\/a-2894-5577","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}